CANCER GENETICS, INC Purchase Agreements
13 Contracts & Agreements
- Equity Purchase Agreement, dated November 2, 2022 by and among Vyant Bio, Inc., Reaction Biology Corporation and vivoPharm Pty, Ltd (Filed With SEC on November 3, 2022)
- Purchase Agreement dated March 28, 2022 between Lincoln Park Capital, LLC and Vyant Bio, Inc (Filed With SEC on March 30, 2022)
- Form of Securities Purchase Agreement, dated February 10, 2021 (Filed With SEC on February 16, 2021)
- Form of Securities Purchase Agreement, dated January 28, 2021 (Filed With SEC on February 1, 2021)
- Asset Purchase Agreement, dated July 5, 2019, by and among siParadigm, LLC and Cancer Genetics, Inc (Filed With SEC on August 19, 2019)
- Secured Creditor Asset Purchase Agreement, dated July 15, 2019, by and among Interpace BioPharma, Inc., Cancer Genetics, Inc., Interpace Diagnostics Group, Inc. and Partners for... (Filed With SEC on July 19, 2019)
- Securities Purchase Agreement (Filed With SEC on July 18, 2018)
- Form of Securities Purchase Agreement, dated December 8, 2017, by and between Cancer Genetics, Inc. and various purchasers named therein (Filed With SEC on December 8, 2017)
- SECURITIES PURCHASE AGREEMENT (Filed With SEC on September 9, 2016)
- SECURITIES PURCHASE AGREEMENT (Filed With SEC on May 20, 2016)
- AMENDED AND RESTATED ASSET PURCHASE AGREEMENT BY AND BETWEEN RESPONSE GENETICS, INC., A DELAWARE CORPORATION AND CANCER GENETICS, INC., A DELAWARE CORPORATION DATED AS OF AUGUST... (Filed With SEC on August 21, 2015)
- ASSET PURCHASE AGREEMENT BY AND BETWEEN RESPONSE GENETICS, INC., A DELAWARE CORPORATION AND CANCER GENETICS, INC., A DELAWARE CORPORATION DATED AS OF AUGUST 9, 2015 Table of... (Filed With SEC on August 10, 2015)
- ASSET PURCHASE AGREEMENT (Filed With SEC on July 22, 2014)
